Clinical Trial Detail

NCT ID NCT02101775
Title Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

peritoneal carcinoma

ovarian carcinoma

fallopian tube carcinoma

Therapies

Gemcitabine

Adavosertib + Gemcitabine

Age Groups: adult

No variant requirements are available.